Company
Harmony
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
1
1 still marketed
Novel approvals
0
Approvals since 2021
2
Originals and new uses
Phase 3 trials
7
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With NarcolepsyPivotal-lookingRecruiting
Harmony Biosciences Management, Inc.Industry
NCT07675135 · 258 participants (planned) · Start Jun 4, 2026 · Primary completion Oct 2027
Drug: HBS-301 · For: EDS; Cataplexy; Fatigue and 1 more
Sites: Birmingham, Alabama; Mobile, Alabama; Peoria, Arizona · 64 sites in all
- A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)Pivotal-lookingRecruiting
Harmony Biosciences Management, Inc.Industry
NCT07500090 · 248 participants (planned) · Start Mar 16, 2026 · Primary completion Oct 2027
Drug: HBS-301 tablet; Placebo · For: Idiopathic Hypersomnia
Sites: Birmingham, Alabama; Mobile, Alabama; Peoria, Arizona · 54 sites in all
- A Study of Pitolisant in Patients With Prader-Willi SyndromePivotal-lookingRecruiting
Harmony Biosciences Management, Inc.Industry
NCT06366464 · 134 participants (planned) · Start May 28, 2024 · Primary completion Apr 2027
Drug: Pitolisant tablet · For: Prader-Willi Syndrome
Sites: Los Angeles, California; Sacramento, California; San Diego, California · 57 sites in all
Marketed drugs (1)
Newest FDA action first.
- Wakix Pitolisant Hydrochloride · 2020
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.